Financial Contrast: Obalon Therapeutics (OBLN) and BRAINSWAY LTD/S (BWAY)

Obalon Therapeutics (NASDAQ:OBLN) and BRAINSWAY LTD/S (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Insider & Institutional Ownership

28.0% of Obalon Therapeutics shares are held by institutional investors. 17.9% of Obalon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Obalon Therapeutics and BRAINSWAY LTD/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Obalon Therapeutics -147.30% -100.59% -42.51%
BRAINSWAY LTD/S N/A N/A N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Obalon Therapeutics and BRAINSWAY LTD/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Obalon Therapeutics 0 3 2 0 2.40
BRAINSWAY LTD/S 0 0 5 0 3.00

Obalon Therapeutics presently has a consensus price target of $2.35, indicating a potential upside of 360.78%. BRAINSWAY LTD/S has a consensus price target of $16.75, indicating a potential upside of 55.09%. Given Obalon Therapeutics’ higher possible upside, equities analysts plainly believe Obalon Therapeutics is more favorable than BRAINSWAY LTD/S.

Valuation & Earnings

This table compares Obalon Therapeutics and BRAINSWAY LTD/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Obalon Therapeutics $9.10 million 1.35 -$37.38 million ($1.96) -0.26
BRAINSWAY LTD/S N/A N/A N/A N/A N/A

BRAINSWAY LTD/S has lower revenue, but higher earnings than Obalon Therapeutics.

Summary

BRAINSWAY LTD/S beats Obalon Therapeutics on 5 of the 9 factors compared between the two stocks.

Obalon Therapeutics Company Profile

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.

Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.